Lineage Cell Therapeutics, Inc. (LCTX) — 10-Q Filings
All 10-Q filings from Lineage Cell Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
LCTX Net Loss Widens to $64.3M on Warrant Liability, Intangible Impairment
— Nov 6, 2025 Risk: high
Lineage Cell Therapeutics, Inc. (LCTX) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $64.259 million, a sub -
Lineage Cell Therapeutics' Q2 Loss Widens Amid R&D Spend
— Aug 12, 2025 Risk: high
Lineage Cell Therapeutics, Inc. reported total revenues of $1.5 million for the six months ended June 30, 2025, a decrease from $2.0 million in the prior year p -
Lineage Cell Therapeutics Files Q1 2025 10-Q
— May 13, 2025 Risk: medium
Lineage Cell Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business operations, inc -
Lineage Cell Therapeutics Files Q3 2024 10-Q
— Nov 14, 2024 Risk: medium
Lineage Cell Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the third qu -
Lineage Cell Therapeutics Q2 2024 Update
— Aug 8, 2024 Risk: medium
Lineage Cell Therapeutics, Inc. reported its financial results for the period ending June 30, 2024. The company's cash and cash equivalents stood at $103.5 mill -
Lineage Cell Therapeutics Files 10-Q for Period Ending March 31, 2024
— May 9, 2024 Risk: medium
Lineage Cell Therapeutics, Inc. (LCTX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Lineage Cell Therapeutics, Inc. filed a 10-Q report for the
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX